ArticleInfection and drug resistance2025
Comparative Prognosis of Fungal Balls Versus Invasive Pulmonary Mucormycosis.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pulmonary mucormycosis is recognized as a highly fatal invasive fungal infection. However, clinical observations have demonstrated unexpectedly favorable outcomes in some patients. This study aimed to compare the clinical presentation, management, and prognosis between patients with fungal balls and invasive pulmonary mucormycosis. Methods: This observational study included patients diagnosed with pulmonary mucormycosis at the Second Xiangya Hospital of Central South University between 2007 and 2023. Based on imaging characteristics, the patients were divided into invasive pulmonary mucormycosis and fungal balls groups, and the underlying diseases, clinical manifestations, diagnostic method, treatment, and prognosis were analyzed. Results: Compared to invasive pulmonary mucormycosis patients, pulmonary mucormycosis patients with fungal balls had fewer systemic underlying diseases, such as diabetes, immunosuppression, and more pre-existing lung diseases like bronchiectasis (82.4%) and tuberculosis (64.7%). They exhibited milder symptoms, mainly cough and sputum, with lower CRP and ESR levels. Pulmonary mucormycosis patients with fungal balls typically involved a single upper lobe, while invasive pulmonary mucormycosis patients often had bilateral lung involvement. Ten pulmonary mucormycosis patients with fungal balls treated surgically without antifungal therapy still had favorable prognoses than those with invasive disease. Conclusion: Compared to invasive pulmonary mucormycosis patients, pulmonary mucormycosis patients with fungal balls exhibit milder clinical symptoms and more favorable prognosis. Surgical intervention might play a critical role in the management of pulmonary mucormycosis patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.